Cargando…

Risk of cardiovascular disease following gonadotropin‐releasing hormone agonists vs antagonists in prostate cancer: Real‐world evidence from five databases

Observational studies in prostate cancer (PCa) have shown an increased risk of cardiovascular disease (CVD) following gonadotropin‐releasing hormone (GnRH) agonists, whereas randomised‐controlled trials have shown no associations. Compared to GnRH agonists, GnRH antagonists have shown less atheroscl...

Descripción completa

Detalles Bibliográficos
Autores principales:	George, Gincy, Garmo, Hans, Scailteux, Lucie‐Marie, Balusson, Frédéric, De Coster, Greet, De Schutter, Harlinde, Kuiper, Josephina G., Oger, Emmanuel, Verbeeck, Julie, Van Hemelrijck, Mieke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2020
Materias:	Cancer Epidemiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8049028/ https://www.ncbi.nlm.nih.gov/pubmed/33186481 http://dx.doi.org/10.1002/ijc.33397

Ejemplares similares

Real‐world insights into risk of developing cardiovascular disease following GnRH agonists versus antagonists for prostate cancer: a methodological protocol to a study using five European databases
por: George, Gincy, et al.
Publicado: (2019)

Prospective study of Type 2 diabetes mellitus, anti‐diabetic drugs and risk of prostate cancer
por: Häggström, Christel, et al.
Publicado: (2016)

Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer
por: Crawley, Danielle, et al.
Publicado: (2016)

Heterogeneity in risk of prostate cancer: A Swedish population‐based cohort study of competing risks and Type 2 diabetes mellitus
por: Häggström, Christel, et al.
Publicado: (2018)

Thyroid cancer incidence near nuclear sites in Belgium: An ecological study at small geographical level
por: Demoury, Claire, et al.
Publicado: (2019)

Association of Gonadotropin-Releasing Hormone Agonists for Prostate Cancer With Cardiovascular Disease Risk and Hypertension in Men With Diabetes
por: Lin, E., et al.
Publicado: (2022)

Exploring the association between use of gonadotropin releasing hormones agonists and prostate cancer diagnosis per se and diabetes control in men with type 2 diabetes mellitus: a nationwide, population-based cohort study
por: Lin, E., et al.
Publicado: (2021)

Serum lactate dehydrogenase and survival following cancer diagnosis
por: Wulaningsih, Wahyu, et al.
Publicado: (2015)

Serum inflammatory markers and colorectal cancer risk and survival
por: Ghuman, Sundeep, et al.
Publicado: (2017)

Susceptibility to SARS‐Cov‐2 infection and risk for severe COVID‐19 in patients with prostate cancer on androgen deprivation therapy
por: Gedeborg, Rolf, et al.
Publicado: (2022)

Progression of breast cancer following locoregional ipsilateral recurrence: importance of interval time
por: Melvin, Jennifer C, et al.
Publicado: (2016)

No generally increased risk of cancer after total hip arthroplasty performed due to osteoarthritis
por: Hailer, Nils P., et al.
Publicado: (2019)

Socio-Economic Position, Cancer Incidence and Stage at Diagnosis: A Nationwide Cohort Study in Belgium
por: Rosskamp, Michael, et al.
Publicado: (2021)

Determinants of non-adherence to adjuvant endocrine treatment in women with breast cancer: the role of comorbidity
por: Wulaningsih, W., et al.
Publicado: (2018)

Use of Antiepileptic Drugs and Risk of Prostate Cancer: A Nationwide Case-Control Study in Prostate Cancer Data Base Sweden
por: George, Gincy, et al.
Publicado: (2023)

Association between baseline serum glucose, triglycerides and total cholesterol, and prostate cancer risk categories
por: Arthur, Rhonda, et al.
Publicado: (2016)

Mortality, cardiovascular risk, and androgen deprivation therapy for prostate cancer: A systematic review with direct and network meta-analyses of randomized controlled trials and observational studies
por: Scailteux, Lucie-Marie, et al.
Publicado: (2016)

Research engagement among black men with prostate cancer
por: Toms, Charlotte, et al.
Publicado: (2016)

Prostate-specific antigen testing in inner London general practices: are those at higher risk most likely to get tested?
por: Nderitu, Paul, et al.
Publicado: (2016)

Circulating adipokine concentrations and risk of five obesity‐related cancers: A Mendelian randomization study
por: Dimou, Niki L., et al.
Publicado: (2020)

Factors associated with interval colorectal cancer after negative FIT: Results of two screening rounds in the Dutch FIT‐based CRC screening program
por: Breekveldt, Emilie C. H., et al.
Publicado: (2022)

Comparative proteomics reveal negative effects of gonadotropin-releasing hormone agonist and antagonist on human endometrium
por: Chen, Qian, et al.
Publicado: (2019)

Editorial Comment to Considerations for the use of gonadotropin‐releasing hormone agonists and antagonists in patients with prostate cancer
por: Kawahara, Takashi
Publicado: (2020)

Survival after radiotherapy versus radical cystectomy for primary muscle‐invasive bladder cancer: A Swedish nationwide population‐based cohort study
por: Häggström, Christel, et al.
Publicado: (2019)

Combining data to perform population-based observational studies: know your sources. The case of thyroid cancer in Belgium
por: Decallonne, Brigitte, et al.
Publicado: (2022)

Modifications in dietary and alcohol intakes between before and after cancer diagnosis: Results from the prospective population‐based NutriNet‐Santé cohort
por: Fassier, Philippine, et al.
Publicado: (2017)

Is there a role for IGF‐1 in the development of second primary cancers?
por: Shanmugalingam, Thurkaa, et al.
Publicado: (2016)

Scoping review protocol: is there a role for physical activity interventions in the treatment pathway of bladder cancer?
por: Mehrotra, Sneha, et al.
Publicado: (2019)

Association between atherogenic lipids and GnRH agonists for prostate cancer in men with T2DM: a nationwide, population-based cohort study in Sweden
por: Lin, E., et al.
Publicado: (2022)

Scoping review protocol: bladder cancer in Nigeria: what are the gaps in clinical care and research?
por: Kibaru, Joyce, et al.
Publicado: (2021)

Serum leptin, C‐reactive protein, and cancer mortality in the NHANES III
por: Wulaningsih, Wahyu, et al.
Publicado: (2015)

A randomized controlled trial of gonadotropin-releasing hormone agonist versus gonadotropin-releasing hormone antagonist in Iranian infertile couples: oocyte gene expression
por: Hoseini, Fatemeh Sadat, et al.
Publicado: (2014)

Dual trigger with gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves oocyte yield in normal responders on GnRH-antagonist cycles
por: Albeitawi, Soha, et al.
Publicado: (2022)

Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Has the Same Effect as Gonadotropin-Releasing Hormone Agonist Injections in Terms of Preparation for Transcervical Resection Myomectomy
por: Ito, Mika, et al.
Publicado: (2022)

Worldwide burden of cancer attributable to HPV by site, country and HPV type
por: de Martel, Catherine, et al.
Publicado: (2017)

Pediatric males receiving hematopoietic stem cell transplant lose their male disadvantage in disease risk after the procedure: A retrospective observational study
por: De Nardi, Laura, et al.
Publicado: (2022)

Real World Data Studies of Antineoplastic Drugs: How Can They Be Improved to Steer Everyday Use in the Clinic?
por: George, Gincy, et al.
Publicado: (2023)

Estimated global cancer incidence in the oldest adults in 2018 and projections to 2050
por: Pilleron, Sophie, et al.
Publicado: (2020)

Associations between early‐life and in utero infections and cytomegalovirus‐positive acute lymphoblastic leukemia in children
por: Gallant, Rachel E., et al.
Publicado: (2022)

Common dietary patterns and risk of cancers of the colon and rectum: Analysis from the United Kingdom Women's Cohort Study (UKWCS)
por: Rada‐Fernandez de Jauregui, Diego, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_h7j34sfo6cn1gcs8ajdqi2cp3r